Logo
Logo


ISSN: 0300-9041
ISSNe: 2594-2034


Indizada en: SciELO, Índice Médico Latinoamericano, LILACS, Medline
Editada por la Federación Mexicana de Colegios de Obstetricia, y Ginecologia AC
Fundada por la Asociación Mexicana de Ginecología y Obstetricia en 1945
 

INFORMACIÓN EXCLUSIVA PARA LOS PROFESIONALES DE LA SALUD


Periodicidad: continua
Abreviatura: Ginecol Obstet Mex
ISSN: 0300-9041
ISSNe: 2594-2034
Indizada en: Scimago, Índice Médico Latinoamericano, Lilacs, Medline, Science Citation Index, Ulrich, Ebsco.

Tumor cardiaco fetal. Reporte de un caso

Fetal cardiac tumor. Report of a case.

Ginecol Obstet Mex. 2020; 88 (9): 638-643.

https://doi.org/10.24245/gom.v88i9.3967

Susana Soto-López,1 Silvia Arévalo-Martínez,2 Elena Carreras-Moratonas,3 Queralt Ferrer-Menduiña4

1 Médico rotante en formación avanzada en Medicina Materno Fetal.
2 Jefe de servicio de la Unidad de Medicina Materno Fetal.
3 Coordinadora médica de Obstetricia y Medicina de la Reproducción.
4 Facultativo  especialista del Departamento de Pediatría y Cardiología Fetal.
Hospital Universitario Vall d´Hebron, Barcelona, España.


Corrrespondencia:

Susana Soto López
susysoto25@gmail.com

Debe citarse como:

Soto-López S, Arévalo-Martínez S, Carreras-Moratonas E, Ferrer-Menduiña Q. Tumor cardiaco fetal. Reporte de un caso. Ginecol Obstet Mex. 2020; 88 (9): 638-643. https://doi.org/10.24245/gom.v88i9.3967

Resumen

ANTECEDENTES: Los tumores cardiacos fetales son excepcionales y se asocian con complicaciones que ponen en riesgo la vida del feto. Se diagnostican a partir del segundo trimestre y pueden provocar hidrops fetal no inmunitario, arritmias, compresión de los conductos de salida y muerte súbita. Es importante el seguimiento durante la gestación para detectar posibles complicaciones y establecer un plan de nacimiento.

CASO CLÍNICO: Paciente de 35 años, multigesta, enviada a la unidad materno-fetal para valoración por embarazo de 24.2 semanas y feto con tumor cardiaco único, localizado en el ápex, de gran tamaño. No se identificó afectación de la función cardiaca, por lo que solo ameritó vigilancia prenatal. Al nacimiento, el recién nacido recibió tratamiento con everolimus, con reacción satisfactoria.

CONCLUSION: El tratamiento y seguimiento de fetos con tumor cardiaco es de suma importancia para detectar complicaciones prenatales y establecer el plan de nacimiento en la unidad de tercer nivel de atención médica.

PALABRAS CLAVE: Tumor cardiaco fetal; hidrops fetal no inmunitario; arritmia; embarazo; diagnóstico prenatal; ecocardiografía; hemangioma; everolimus.

Abstract

BACKGROUND: Fetal cardiac tumors are rare, with a very low incidence, however; when they do occur, they are associated with life-threatening complications of the fetus. They are diagnosed from the second trimester and can cause non-immune fetal hydrops, arrhythmias, compression of outflow tracts, and sudden fetal death. Follow-up during pregnancy is important to detect possible complications and establish a birth plan.

CLINICAL CASE: A 35-year-old multigest patient, sent to the fetal maternal unit by his treating physician for evaluation for 24.2-week pregnancy and fetus with a single cardiac tumor, located on the apex, of large size; and without compromise in cardiac function, so only prenatal surveillance was warranted. At birth, the newborn received everolimus treatment, with a good response.

CONCLUSION: The case of a patient with a single pregnancy and fetus with a prenatal diagnosis of a large cardiac tumor is presented with a family history of hemangiomas. In this case, a follow-up approach to detect prenatal complications and establish a birth plan in a third level of medical care is critical for a good practice.

KEYWORDS: Fetal cardiac tumors; Non immune fetal hydrops; Arrhythmias; pregnancy; Prenatal diagnosis; Echocardiography; Everolimus.

    1. Isaacs H. Fetal and Neonatal cardiac tumor. Pediatr Cardiol 2004; 25: 252-73. doi: 10.1007/S00246-003-0590-4.
    2. Geipel A, et al. Perinatal diagnosis of cardiac tumors. Ultrasound Obstet Gynecol 2001; 17: 17-21. https://doi.org/10.1046/j.1469-0705.2001.00314.x
    3. Baird C, et al. Right atrial hemangioma in the newborn: Utility of fetal imaging. Ann Pediatr Cardiol 2012; 5 (1): 81-84. doi: 10.4103/0974-2069.93719.
    4. Yuan S. Fetal primary cardiac tumors during perinatal period. Pediatrics and neonatology 2017; 58: 205-10. http://dx.doi.org/10.1016/j.pedneo.2016.07.004.
    5. Holley D, et al. Diagnosis and management of fetal cardiac tumors: A multicenter experience and review of published reports. J Am Coll Cardiol 1995; 26 (2): 516-20. https://doi.org/10.1016/0735-1097(95)80031-B.
    6. Yates J. Tuberous sclerosis. Eur J Hum Gen 2006; 14: 106-173. doi: 10.1038/sj.ejhg.5201625.
    7. Bader R, et al. Fetal rhabdomyoma: prenatal diagnosis, clinical outcome and incidence of associated tuberous sclerosis complex. J Pediatr 2003; 143: 620-4. doi: https://doi.org/10.1067/S0022-3476(03)00494-3.
    8. Northrup H, Krueger D. Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology 2012; 49: 243-54. doi: 10.1016/j.pediatrneurol.2013.08.001.
    9. Das B, Sharma J. Cardiac Rhabdomyoma and tuberous sclerosis: prenatal diagnosis and follow-up. Indian J Pediat 2003; 70 (1): 87-89. doi: 10.1007/bf02722750.
    10. Milunsky A, et al. Prenatal molecular diagnosis of tuberous sclerosis complex. Am J Obstet Gynecol 2009; 200: 321.e1-321.e6. doi: 10.1016/j.ajog.2008.11.004.
    11. Demir A, et al. Everolimus: A Challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma. Pediatrics 2012; 130: e243-e247. https://doi.org/10.1542/peds.2011-3476.
    12. Nair A, et al. Spontaneous regression of a gigantic cardiac rhabdomyoma. Heart Lung Circ 2017; 26 (11) e105-e106. doi: 10.1016/j.hlc.2017.02.019.
    13. Hoshal S, et al. Regression of massive cardiac rhabdomyoma on everolimus therapy. Pediatr Int 2016; 58 (5): 397-99. https://doi.org/10.1111/ped.12816.
    14. Uzun O, et al. Cardiac tumours in children. Orphan J Rare Dis 2007; 2: 1-14. doi: 10.1186/1750-1172-2-11.
    15. Leithiser R, et al. Prenatal sonographic diagnosis of atrial hemangioma. AJR Am J Roentgenol 1988; 147: 1207-8. doi: 10.2214/ajr.147.6.1207.
    16. Li W, et al. Cardiac hemangioma: A comprehensive analysis of 200 cases. Ann Thorac Surg 2015; 99: 2246-52. https://doi.org/10.1016/j.athoracsur.2015.02.064.
    17. Lacey S, et al. Fetal cardiac tumors: prenatal diagnosis and outcome. Pediatr Cardiol. 2007; 28: 61-67. https://doi.org/10.1007/s00246-005-0876-9.
    18. Dennis M, et al. The echocardiographic diagnosis of multiple fetal cardiac tumors. J Ultrasound Med. 1985; 4: 327-329. doi: 10.7863/jum.1985.4.6.327.
    19. Gu X, et al. Antenatal screening and diagnosis of tuberous sclerosis complex by fetal echocardiography and targeted genomic sequencing. Medicine 2018; 97: 15 (e0112). http://dx.doi.org/10.1097/MD.0000000000010112.
    20. Gresser C, et al. Fetal cardiac tumor: A prenatal echocardiographic marker for tuberous sclerosis. Am J Obstet Gynecol 1987; 156: 689-90. https://doi.org/10.1016/0002-9378(87)90079-2.
    21. Zhou Q, et al. Prenatal echocardiographic differential diagnosis of fetal cardiac tumors. Ultrasound Obstet Gynecol 2004; 23: 165-71. doi: 10.1002/uog.979

Comentarios